<p><strong>Gapping down:</strong> </p><p><u>Select European financial names showing weakness</u>: IRE -4.1%, LYG -3.1%, RBS -3.1%, HBC -2.4%, AIB -2.1%, ING -2.0%, CS -1.9%, UBS -1.5%... <u>Select metals/mining related names trading lower:</u> IAG -3.2%, GOLD -3.1%, AU -3.0%, AUY -2.3%, KGC -2.3%, SLW -2.2%, SLV -2.1%, RTP -1.9% (Rio Tinto and BHP Billiton sign deal on ore venture - NY Times), EGO -1.8%, AEM -1.7%, NEM -1.6%, GG -1.6%, GLD -1.5%, BBL -1.3%, BHP -1.2% (Rio Tinto and BHP Billiton sign deal on ore venture - NY Times), HMY -1.1%... <u>Select airlines ticking lower</u>: CAL -4.6%, DAL -2.4%, LCC -1.8%...<u> Other news</u>: SOMX -67.4% (receives Complete Response Letter from the FDA for Silenor NDA), CHINA -6.1% (announces additional purchase of convertible notes), AXL -5.5% (announced a 14 mln share common stock offering)... <u>Analyst comments</u>: BARE -5.4% (downgraded to Sell from Neutral at Goldman- Reuters), ZLC -5.2% (downgraded to Sell from Hold at Soleil), AAP -1.8% (light volume; downgraded to Underperform at FBR), SI -1.6% (downgraded to Equal Weight from Overweight at Morgan Stanley), CREE -1.2% (downgraded to Market Perform at Morgan Keegan), JNPR -1.2% (downgraded to Sell at Auriga), STO -1.0% (downgraded to Sell from Hold at Deutsche Bank).</p><p><strong>Gapping up:</strong></p><p><u>In reaction to strong earnings/guidance</u>: AKAM +5.7%... <u>M&A news</u>: ROY +46.1% (informed by Franco-Nevada of its intention to make an offer for IRC for C$6.75/share in cash), TRA +8.8% (CF Industries increases offer for Terra Industries by $4.75 cash/share for new value of $45.91/share)... <u>Other news</u>: ATSI +13.8% (light volume; announces CE Mark approval for the ATS 3f enable bioprosthesis), GSM +10.7% (Cramer makes positive comments on MadMoney), MDR +8.9% (plans to separate into two independent companies: Babcock & Wilcox and J. Ray McDermott), CTIC +6.8% (Pixantrone produces 250% relative improvement in 1 year progression free survival for patients with relapsed/refractory, aggressive NHL), SGEN +5.1% (reports "positive" data from phase I weekly-dosing clinical trial of Brentuximab Vedotin in lymphoma), SNTS +4.2% (receives FDA approval for immediate-release omeprazole tablet with dual buffers), TASR +4.2% (receives order for 140 TASER X26 ECDs from Colombian National Police; the order is expected to ship in the fourth quarter of 2009), ALTH +2.0% (reports new analyses of data from PROPEL trial of FOLOTYN), PCL +1.9% (Cramer makes positive comments on MadMoney), DAI +1.2% (sees Mercedes sales up significantly in Q4 - Reuters.com)... <u>Analyst comments</u>: NYB +10.3% (upgraded to Outperform at FBR), SPWRA +5.2% (upgraded to Overweight at Barclays), JASO +4.5% (upgraded to Overweight at Barclays), AMD +3.7% (upgraded to Outperform from Underperform at Bernstein), BRCD +2.8% (upgraded to Outperform at Oppenheimer), STP +2.7% (upgraded to Overweight at Barclays), CMI +2.4% (Hearing added to Buy List at tier 1 firm), POT +1.8% (upgraded to Buy from Neutral at Goldman- Reuters).</p>